Methodology: each issue's direction is a live signal — long/short opens or holds a position, neutral means flat, and every direction change opens, flips, or closes it. Returns are direction-aware (a short gains when the price falls) and compound across positions from first observation to the latest issue. "Price move" is the stock's own raw change, shown separately. Neither represents actual portfolio performance.
Brief History (2 issues)
Up 8.71% capping an extraordinary 145.0% week, with RSI at 62.4 above the 50-day at $9.81 and 200-day at $7.97; a clinical-stage biotech with no earnings anchor after such a move. Sidelines.
Down 38.01% after FDA reviewers deemed the single-arm study 'not interpretable'. RP1 is on its third filing after two complete response letters, with an advisory meeting July 30 and a decision due August 2 — a binary event bet; not participating